Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM, Wen PY. Kesari S, et al. Among authors: lafrankie d. Clin Cancer Res. 2009 Jan 1;15(1):330-7. doi: 10.1158/1078-0432.CCR-08-0888. Clin Cancer Res. 2009. PMID: 19118062 Clinical Trial.
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE, Wen PY. Drappatz J, et al. Among authors: lafrankie dc. Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):85-90. doi: 10.1016/j.ijrobp.2009.07.1741. Epub 2010 Feb 4. Int J Radiat Oncol Biol Phys. 2010. PMID: 20137866 Clinical Trial.
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY. Norden AD, et al. Among authors: lafrankie d. Neuro Oncol. 2013 Jul;15(7):930-5. doi: 10.1093/neuonc/not040. Epub 2013 Apr 3. Neuro Oncol. 2013. PMID: 23553268 Free PMC article. Clinical Trial.
Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma.
Lee EQ, Duda DG, Muzikansky A, Gerstner ER, Kuhn JG, Reardon DA, Nayak L, Norden AD, Doherty L, LaFrankie D, Stefanik J, Vardam T, Smith KH, McCluskey C, Gaffey S, Batchelor TT, Jain RK, Wen PY. Lee EQ, et al. Among authors: lafrankie d. Clin Cancer Res. 2018 Oct 1;24(19):4643-4649. doi: 10.1158/1078-0432.CCR-18-1025. Epub 2018 Jun 25. Clin Cancer Res. 2018. PMID: 29941486 Clinical Trial.
A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.
Drappatz J, Wong ET, Schiff D, Kesari S, Batchelor TT, Doherty L, Lafrankie DC, Ramakrishna N, Weiss S, Smith ST, Ciampa A, Zimmerman J, Ostrowsky L, David K, Norden A, Barron L, Sceppa C, Black PM, Wen PY. Drappatz J, et al. Among authors: lafrankie dc. Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):222-7. doi: 10.1016/j.ijrobp.2008.03.046. Epub 2008 May 29. Int J Radiat Oncol Biol Phys. 2009. PMID: 18513880 Clinical Trial.
Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients.
Norden AD, Bartolomeo J, Tanaka S, Drappatz J, Ciampa AS, Doherty LM, Lafrankie DC, Ruland S, Quant EC, Beroukhim R, Wen PY. Norden AD, et al. Among authors: lafrankie dc. J Neurooncol. 2012 Jan;106(1):121-5. doi: 10.1007/s11060-011-0642-1. Epub 2011 Jun 26. J Neurooncol. 2012. PMID: 21706358
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.
Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Doherty LM, LaFrankie DC, Pulverenti JR, Rifenburg JA, Ruland SF, Smith KH, Gaffey SC, McCluskey C, Ligon KL, Reardon DA, Wen PY. Norden AD, et al. Among authors: lafrankie dc. J Neurooncol. 2015 Jan;121(2):297-302. doi: 10.1007/s11060-014-1631-y. Epub 2014 Oct 22. J Neurooncol. 2015. PMID: 25338318 Clinical Trial.
20 results